Zealand Pharma Valuation
| ZEAL Stock | DKK 723.00 15.50 2.10% |
At this time, the company appears to be overvalued. Zealand Pharma AS maintains a prevalent Real Value of kr592.86 per share. The last-minute price of the company is kr723.0. Our model calculates the value of Zealand Pharma AS from examining the company fundamentals such as Return On Asset of -0.48, shares outstanding of 51.28 M, and Operating Margin of (3.82) % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Zealand Pharma's price fluctuation is very steady at this time. Calculation of the real value of Zealand Pharma AS is based on 3 months time horizon. Increasing Zealand Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Zealand Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zealand Stock. However, Zealand Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 723.0 | Real 592.86 | Hype 723.0 |
The intrinsic value of Zealand Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Zealand Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Zealand Pharma AS helps investors to forecast how Zealand stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zealand Pharma more accurately as focusing exclusively on Zealand Pharma's fundamentals will not take into account other important factors: Zealand Pharma Total Value Analysis
Zealand Pharma AS is at this time estimated to have takeover price of 10.33 B with market capitalization of 11.16 B, debt of 647.91 M, and cash on hands of 1.28 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Zealand Pharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.33 B | 11.16 B | 647.91 M | 1.28 B |
Zealand Pharma Investor Information
About 56.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.31. Zealand Pharma AS recorded a loss per share of 23.13. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Zealand Pharma's financial statements, Zealand Pharma AS is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Zealand Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Zealand Pharma has an asset utilization ratio of 14.15 percent. This suggests that the Company is making kr0.14 for each dollar of assets. An increasing asset utilization means that Zealand Pharma AS is more efficient with each dollar of assets it utilizes for everyday operations.Zealand Pharma Ownership Allocation
Zealand Pharma AS retains a total of 51.28 Million outstanding shares. Over half of Zealand Pharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Zealand Pharma AS. Please watch out for any change in the institutional holdings of Zealand Pharma AS as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Zealand Pharma Profitability Analysis
The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M.About Zealand Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Zealand Pharma AS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Zealand Pharma AS based exclusively on its fundamental and basic technical indicators. By analyzing Zealand Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Zealand Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Zealand Pharma. We calculate exposure to Zealand Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zealand Pharma's related companies.Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.
8 Steps to conduct Zealand Pharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Zealand Pharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Zealand Pharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Zealand Pharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Zealand Pharma's revenue streams: Identify Zealand Pharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Zealand Pharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Zealand Pharma's growth potential: Evaluate Zealand Pharma's management, business model, and growth potential.
- Determine Zealand Pharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Zealand Pharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.